Longitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption

Infection

Volumn 39, Issue 2, 2011, Pages 121-126

  Bagaglio, S ^a   Bianchi, G ^b   Danise, A ^a   Porrino, L ^a   Uberti Foppa, C ^a   Lazzarin, A ^a,c   Castagna, A ^a   Morsica, G ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

HAART interruption; HBV DNA; HIV 1; Lamivudine monotherapy; Occult infection; Transaminases flare

Indexed keywords

AMINOTRANSFERASE; DNA POLYMERASE; HEPATITIS B ANTIBODY; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS DNA;

ADULT; ARTICLE; CD4 CD8 RATIO; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMALE; FOLLOW UP; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MALE; PILOT STUDY; QUANTITATIVE ANALYSIS; SEQUENCE ANALYSIS; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMORBIDITY; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; SEQUENCE ANALYSIS, DNA;

EID: 79955641984     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-011-0093-9     Document Type: Article

References (19)

1. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol. 2007;46:160-70. (Pubitemid 44827430)
2. Fang Y, Shang QL, Liu JY, et al. Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. J Infect. 2009;58:383-8.
3. Jardim RN, Gonçales NS, Pereira JS, Fais VC, Gonçales Junior FL. Occult hepatitis B virus infection in immunocompromised patients. Braz J Infect Dis. 2008;12:300-5.
4. Piroth L, Lafon ME, Binquet C, et al. Occult hepatitis B in HIV-HCV coinfected patients. Scand J Infect Dis. 2008;31:1-5.
5. Fabris P, Biasin MR, Giordani MT, et al. Impact of occult HBV infection in HIV/HCV co-infected patients: HBV-DNA detection in liver specimens and in serum samples. Curr HIV Res. 2008;6:173-9. (Pubitemid 351479797)
6. Kellerman S, Hanson D, McNaghten A, Fleming P. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in HIV-infected subjects. J Infect Dis. 2003;188:571-7. (Pubitemid 37011810)
7. Chamorro AJ, Casado JL, Bellido D, Moreno S. Reactivation of hepatitis B in an HIV-infected patient with antibodies against hepatitis B core antigen as the only marker. Eur J Clin Microbiol Infect Dis. 2005;24:492-4. (Pubitemid 41124504)
8. Bloquel B, Jeulin H, Burty C, Letranchant L, Rabaud C, Venard V. Occult hepatitis B infection in patients infected with HIV: report of two cases of hepatitis B reactivation and prevalence in a hospital cohort. J Med Virol. 2010;82:206-12.
9. Schnepf N, Sellier P, Bendenoun M, Sanson-le Pors MJ, Mazeron MC. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy. J Clin Virol. 2007;39:48-50. (Pubitemid 46584828)
10. Clark SJ, Creighton S, Horner M, et al. Reactivation of latent hepatitis B virus infection with HIV-related immunosuppression. Int J STD AIDS. 2006;17:67-9. (Pubitemid 43110462)
11. Castagna A, Danise A, Menzo S, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS. 2006;20:795-803. (Pubitemid 43731560)
12. Morsica G, Ancarani F, Bagaglio S, et al. Occult hepatitis B virus infection in a cohort of HIV positive patients: correlation with hepatitis C virus coinfection, virological and immunological features. Infection. 2009;37:445-9.
13. Morsica G, Bagaglio S, Cicconi P, et al. Viral interference between Hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. J Acquir Immune Defic Syndr. 2009;51:574-81.
14. Piroth L, Binquet C, Vergne M, et al. The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. J Hepatol. 2002;36:681-6. (Pubitemid 34499406)
15. Filippini P, Coppola N, Pisapia R, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS. 2006;20:1253-60. (Pubitemid 44030373)
16. Laguno M, Larrousse M, Blanco JL, et al. Prevalence and clinical relevance of occult hepatitis B in the fibrosis progression and antiviral response to INF therapy in HIV-HCV-coinfected patients. AIDS Res Hum Retroviruses. 2008;24:547-53. (Pubitemid 351571046)
17. Allain JP, Belkhiri D, Vermeulen M, et al. Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology. 2009;49:1868-76.
18. Nebbia G, Garcia-Diaz A, Ayliffe U, et al. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol. 2007;79:1464-71. (Pubitemid 47328734)
19. Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol. 2009;8:441-5.